Render Target: SSR
Render Timestamp: 2024-08-29T22:32:56.144Z
Commit: 419142f0105700b709b94a8ebde4734bae2c62a3
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TAF-Iα (F3E2E) Rabbit mAb #97411

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 45
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TAF-Iα (F3E2E) Rabbit mAb recognizes endogenous levels of total TAF-Iα protein. This antibody does not cross-react with TAF-Iβ protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro8 of human TAF-Iα protein.

    Background

    Templated activating factor I (TAF-I), also known as SET, is a histone chaperone protein first discovered to play a role in adenovirus chromatin replication (1,2). TAF-I is an acidic protein capable of binding histone cores and remodeling nucleosomes (3). TAF-I is part of the inhibitor of acetyltransferases (INHAT) complex, which sharply represses histone acetylation by PCAF and P300/CBP (4). INHAT complex binding to histone tails is affected by certain histone marks (5). TAF-I has two predominant isoforms, TAF-Iα and TAF-Iβ, which only differ in the N-terminus. TAF-Iα is the predominant isoform in embryonic stem cells, and its expression is regulated by pluripotent factors. Upon differentiation, an isoform shift takes place as the alternative promoter is upregulated, generating TAF-Iβ (6-8). TAF-I uniquely exhibits histone chaperone activity toward linker histone H1, regulating higher-order chromatin structure. TAF-Iα has less activity than TAF-Iβ due to its inhibitory interaction between its unique N-terminus and the C-terminus (9,10). TAF-I has been implicated in oncogenic transformation by inhibiting apoptosis (11).

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.